Home > Publications Database > Regional locus coeruleus degeneration is uncoupled from noradrenergic terminal loss in Parkinson's disease. > print

001     163310
005     20240305153450.0
024 7 _ |a 10.1093/brain/awab236
|2 doi
024 7 _ |a pmid:34196700
|2 pmid
024 7 _ |a 0006-8950
|2 ISSN
024 7 _ |a 1460-2156
|2 ISSN
024 7 _ |a altmetric:108531568
|2 altmetric
037 _ _ |a DZNE-2022-00090
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Doppler, Christopher E J
|0 0000-0002-1341-0389
|b 0
245 _ _ |a Regional locus coeruleus degeneration is uncoupled from noradrenergic terminal loss in Parkinson's disease.
260 _ _ |a Oxford
|c 2021
|b Oxford Univ. Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1709649269_29109
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Previous studies have reported substantial involvement of the noradrenergic system in Parkinson's disease. Neuromelanin-sensitive MRI sequences and PET tracers have become available to visualize the cell bodies in the locus coeruleus and the density of noradrenergic terminal transporters. Combining these methods, we investigated the relationship of neurodegeneration in these distinct compartments in Parkinson's disease. We examined 93 subjects (40 healthy controls and 53 Parkinson's disease patients) with neuromelanin-sensitive turbo spin-echo MRI and calculated locus coeruleus-to-pons signal contrasts. Voxels with the highest intensities were extracted from published locus coeruleus coordinates transformed to individual MRI. To also investigate a potential spatial pattern of locus coeruleus degeneration, we extracted the highest signal intensities from the rostral, middle, and caudal third of the locus coeruleus. Additionally, a study-specific probabilistic map of the locus coeruleus was created and used to extract mean MRI contrast from the entire locus coeruleus and each rostro-caudal subdivision. Locus coeruleus volumes were measured using manual segmentations. A subset of 73 subjects had 11C-MeNER PET to determine noradrenaline transporter density, and distribution volume ratios of noradrenaline transporter-rich regions were computed. Patients with Parkinson's disease showed reduced locus coeruleus MRI contrast independently of the selected method (voxel approaches: P < 0.0001, P < 0.001; probabilistic map: P < 0.05), specifically on the clinically-defined most affected side (P < 0.05), and reduced locus coeruleus volume (P < 0.0001). Reduced MRI contrast was confined to the middle and caudal locus coeruleus (voxel approach, rostral: P = 0.48, middle: P < 0.0001, and caudal: P < 0.05; probabilistic map, rostral: P = 0.90, middle: P < 0.01, and caudal: P < 0.05). The noradrenaline transporter density was lower in patients with Parkinson's diseasein all examined regions (group effect P < 0.0001). No significant correlation was observed between locus coeruleus MRI contrast and noradrenaline transporter density. In contrast, the individual ratios of noradrenaline transporter density and locus coeruleus MRI contrast were lower in Parkinson's disease patients in all examined regions (group effect P < 0.001). Our multimodal imaging approach revealed pronounced noradrenergic terminal loss relative to cellular locus coeruleus degeneration in Parkinson's disease; the latter followed a distinct spatial pattern with the middle-caudal portion being more affected than the rostral part. The data shed first light on the interaction between the axonal and cell body compartments and their differential susceptibility to neurodegeneration in Parkinson's disease, which may eventually direct research towards potential novel treatment approaches.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a MeNER
|2 Other
650 _ 7 |a Parkinson’s disease
|2 Other
650 _ 7 |a neuromelanin
|2 Other
650 _ 7 |a noradrenaline
|2 Other
650 _ 7 |a positron emission tomography
|2 Other
650 _ 7 |a Norepinephrine Plasma Membrane Transport Proteins
|2 NLM Chemicals
650 _ 7 |a SLC6A2 protein, human
|2 NLM Chemicals
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Aged, 80 and over
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Locus Coeruleus: diagnostic imaging
|2 MeSH
650 _ 2 |a Locus Coeruleus: metabolism
|2 MeSH
650 _ 2 |a Magnetic Resonance Imaging: methods
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Multimodal Imaging: methods
|2 MeSH
650 _ 2 |a Norepinephrine Plasma Membrane Transport Proteins: metabolism
|2 MeSH
650 _ 2 |a Parkinson Disease: diagnostic imaging
|2 MeSH
650 _ 2 |a Parkinson Disease: metabolism
|2 MeSH
650 _ 2 |a Positron-Emission Tomography: methods
|2 MeSH
700 1 _ |a Kinnerup, Martin B
|b 1
700 1 _ |a Brune, Corinna
|b 2
700 1 _ |a Farrher, Ezequiel
|b 3
700 1 _ |a Betts, Matthew
|0 P:(DE-2719)2810555
|b 4
|u dzne
700 1 _ |a Fedorova, Tatyana D
|b 5
700 1 _ |a Schaldemose, Jeppe L
|b 6
700 1 _ |a Knudsen, Karoline
|b 7
700 1 _ |a Ismail, Rola
|b 8
700 1 _ |a Seger, Aline D
|b 9
700 1 _ |a Hansen, Allan K
|b 10
700 1 _ |a Stær, Kristian
|b 11
700 1 _ |a Fink, Gereon R
|b 12
700 1 _ |a Brooks, David J
|0 0000-0003-2602-2518
|b 13
700 1 _ |a Nahimi, Adjmal
|b 14
700 1 _ |a Borghammer, Per
|0 0000-0001-6391-8052
|b 15
700 1 _ |a Sommerauer, Michael
|0 0000-0001-5723-9766
|b 16
773 _ _ |a 10.1093/brain/awab236
|g Vol. 144, no. 9, p. 2732 - 2744
|0 PERI:(DE-600)1474117-9
|n 9
|p 2732 - 2744
|t Brain
|v 144
|y 2021
|x 1460-2156
909 C O |p VDB
|o oai:pub.dzne.de:163310
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)2810555
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2021
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-01-29
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-29
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2022-11-09
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2022-11-09
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b BRAIN : 2021
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-09
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-09
915 _ _ |a IF >= 15
|0 StatID:(DE-HGF)9915
|2 StatID
|b BRAIN : 2021
|d 2022-11-09
920 1 _ |0 I:(DE-2719)5000006
|k AG Düzel
|l Clinical Neurophysiology and Memory
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)5000006
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21